Preferred Label : Lisdexamfetamine Dimesylate;

MeSH definition : A dextroamphetamine drug precursor that also functions as a CENTRAL NERVOUS SYSTEM STIMULANT and DOPAMINE UPTAKE INHIBITOR and is used in the treatment of ATTENTION DEFICIT HYPERACTIVITY DISORDER.;

MeSH synonym : Dimesylate, Lisdexamfetamine; Lis-dexamfetamine Dimesylate; Dimesylate, Lis-dexamfetamine; Lis dexamfetamine Dimesylate;

MeSH Hyperonym : lisdexamfetamine;

MeSH hyponym : elvanse; vyvanse; NRP104; NRP-104; NRP 104;

MeSH Related Number : H645GUL8KJ;

Wikipedia link : https://en.wikipedia.org/wiki/Elvanse;

Is substance : O;

UNII : SJT761GEGS;

Details


Main resources

You can consult :

A dextroamphetamine drug precursor that also functions as a CENTRAL NERVOUS SYSTEM STIMULANT and DOPAMINE UPTAKE INHIBITOR and is used in the treatment of ATTENTION DEFICIT HYPERACTIVITY DISORDER.

https://www.has-sante.fr/jcms/p_3699640/fr/xurta-lisdexamphetamine-trouble-deficitaire-de-l-attention-avec-ou-sans-hyperactivite-tdah-chez-l-adulte-et-l-enfant-age-de-6-ans-et-plus
2025
false
false
false
France
treatment outcome
insurance, health, reimbursement
attention deficit disorder with hyperactivity
Lisdexamfetamine Dimesylate
central nervous system stimulants
administration, oral
lisdexamfetamine
child
adolescent
adult
Product containing precisely lisdexamfetamine dimesylate 50 milligram/1 each conventional release oral capsule (clinical drug)
Product containing precisely lisdexamfetamine dimesylate 60 milligram/1 each conventional release oral capsule (clinical drug)
Product containing precisely lisdexamfetamine dimesylate 70 milligram/1 each conventional release oral capsule (clinical drug)
attention deficit and disruptive behavior disorders
evaluation of the transparency committee

---
https://www.inesss.qc.ca/publications/repertoire-des-publications/publication/portraits-decrivant-les-interventions-pharmacologiques-et-non-pharmacologiques-entourant-le-trouble-du-deficit-de-lattention-avec-ou-sans-hyperactivite-tdah-chez-les-quebecois-de-25-ans-et-moins.html
2017
false
false
false
Canada
French
practice guideline
attention deficit disorder with hyperactivity
child
adolescent
young adult
quebec
review of literature
central nervous system stimulants
methylphenidate
dextroamphetamine
Delayed-Action preparations
Lisdexamfetamine Dimesylate
Atomoxetine Hydrochloride
centrally acting sympathomimetics
age factors
sex factors
drug utilization
drug utilization

---
https://www.inesss.qc.ca/thematiques/medicaments/medicaments-evaluation-aux-fins-dinscription/extrait-davis-au-ministre/vyvanse-3432.html
2016
false
Canada
French
English
Lisdexamfetamine Dimesylate
evaluation of the transparency committee
attention deficit disorder with hyperactivity
child
adolescent
lisdexamfetamine
central nervous system stimulants
prodrugs
treatment outcome
Cost-Benefit analysis
adult
clinical trials as topic
administration, oral
drug evaluation

---
Summary Basis of Decision (SBD) VYVANSE - lisdexamfetamine dimesylate
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailOne.php?lang=fr&linkID=SBD00311
2010
false
Canada
French
English
Lisdexamfetamine Dimesylate
drug approval
canada
attention deficit disorder with hyperactivity
prodrugs
central nervous system stimulants
capsules
administration, oral
child
lisdexamfetamine
drug information

---
https://www.cadth.ca/sites/default/files/cdr/complete/cdr_complete_Vyvanse-December-18-2009_f.pdf
2009
false
Canada
French
Lisdexamfetamine Dimesylate
Lisdexamfetamine Dimesylate
attention deficit disorder with hyperactivity
canada
insurance, health, reimbursement
child
randomized controlled trials as topic
Cost-Benefit analysis
treatment outcome
lisdexamfetamine
drug evaluation

---
Nous contacter.
08/11/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.